Interview with Greater Geneva Bern area (GGBa) (January 2024)
News and releases
Categories
- Academia (4)
- Corporate news (21)
- Covid-19 (11)
- Industry (2)
- Press releases (4)
- Public Funds (3)
- SWE adjuvant (6)
28. September 2023
GVIRF webinar “Vaccine Adjuvants for Global Health”
VFI was invited to present at the GVIRF webinar "Vaccine Adjuvants for Global Health" organized on the 13th of September by NIH/NIAID, the Bill & Melinda Gates Foundation and the World Health Organization. As an introductory presentation of the webinar, our CEO Nicolas Collin shared his views on the Needs for an Adjuvant Global Market including the requirements to ensure global capacity, equitable access, and affordability of adjuvanted vaccines. During Session III, Céline Lemoine, Head of VFI Lausanne laboratories, provided an overview of our Adjuvant Portfolio to support the development of adjuvanted vaccines worldwide. These presentations highlighted VFI’s dedication to innovation and collaboration in the field of vaccine adjuvants in the fight against infectious diseases.
Feel free to download and share these presentations and do not hesitate to contact us for further information on VFI activities, projects and collaboration opportunities.
Presentation "Vaccine adjuvants: needs for a Global Market" (Nicolas Collin, page 1-15)
Presentation "VFI Adjuvant Portfolio" (Céline Lemoine, page 56-61)
01. May 2023
TBVAC Horizon – A boost for research towards a better understanding of local lung immunity to tuberculosis infection
VFI is pleased to pursue its collaboration with TBVAC in the pursuit of a safe and effective vaccine against tuberculosis. VFI will provide adjuvants and formulation expertise to accelerate the development of TBVAC's promising vaccine candidates, and to advance towards a world without tuberculosis. The VFI team is proud to be part of this crucial effort and look forward to the positive impact our work will have on public health.
For News release read here
28. April 2023
VIDO and VFI collaborate to strengthen pandemic preparedness
The Vaccine Formulation Institute (VFI) and the Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan (USask) have signed a collaborative research agreement to help drive joint vaccine development.
Read press release here.
14. March 2022
ISIDORe – “Integrated Services for Infectious Disease Outbreak Research” – officially launched
ISIDORe - “Integrated Services for Infectious Disease Outbreak Research”, has been officially launched on 24 February 2022. This 21M€ EU-funded large-scale project assembles an unprecedented One Health-driven, integrated portfolio of cutting-edge research services and resources, dedicated to the study of epidemic-prone diseases including SARS-CoV-2 variants. VFI offers a range of TransNational Access Services on adjuvants and formulation expertise in order to fight epidemic diseases.
For Press release read here
16. November 2021
CEPI awards VIDO and VFI for COVID-19 variants vaccine development
VFI is pleased to announce its continued partnership with VIDO, thanks to a 5M USD award from CEPI (Coalition of Epidemics Preparedness Innovations), to develop new vaccines that are broadly protective against COVID-19 variants and suitable for use in Low- and Middle-Income Countries. This work builds on the development of COVAC-2, VIDO’s subunit vaccine formulated with Sepivac SWE™, an adjuvant co-developed by Seppic and VFI.
Click here to read VIDO press release and CEPI press release
28. June 2021
USask’s VIDO announces positive Phase 1 results for COVAC-2
VFI is pleased to share news on positive Phase 1 results for COVAC-2, a COVID-19 subunit vaccine candidate developed by Usask's VIDO, formulated with Sepivac SWE™️, an adjuvant developed by VFI and Seppic. Click here to read the press release.
05. February 2021
Start of COVAC-2 phase 1 clinical trial
Start of COVAC-2 phase 1 clinical trial! A COVID-19 vaccine developed by VIDO which includes the open-access adjuvant Sepivac SWE, co-developed by VFI and Seppic.
07. January 2021
VIDO’s COVID-19 vaccine receives Health Canada clinical trial approval
VIDO’s COVID-19 vaccine receives Health Canada clinical trial approval for subunit-based vaccine combined to the open-access adjuvant Sepivac SWE, that was developed by Seppic in collaboration with VFI. First-in-human trials are planned in January 2021.
04. December 2020
The Vaccine Formulation Institute’s squalene-in-water adjuvant SWE is now available from our partner Seppic under the name Sepivac SWE™
Sepivac SWE™ is prepared at cGMP-grade and is being made available to the entire vaccine community under open-access terms. Sepivac SWE™ adjuvant can be used in the composition of several vaccines including vaccines against seasonal influenza, pandemic influenza and COVID-19. A production capacity of several hundred million doses per year of Sepivac SWE™ is expected by summer 2021.
VFI is proud to have co-led the development of the first open-access adjuvant for prophylactic use since aluminium salts in the 1920’s and is grateful to its initial funders (European Commission, US-HHS BARDA and GIZ) for having catalysed the development of the SWE adjuvant. We look forward to continuing this long-term partnership with our Seppic colleagues.
12. November 2020
VFI’s fight against Coronavirus during 2nd wave of COVID pandemic
With fitting measures, VFI laboratories will remain operational during the second wave of COVID-19 pandemic. We continue our vaccine development efforts in collaboration with the Bill & Melinda Gates Foundation and other partners in order to develop rapid solutions against the pandemic.
12. November 2020
VFI presentation at Biopôle Workshops
Following the opening of our new laboratories, VFI was invited to introduce our work on adjuvants and vaccine formulations to the Biopôle Lausanne community. We look forward to future Biopôle collaborations!
02. November 2020
Webinar: Regulatory information for veterinary vaccine development in the EU and where to find it:
As partner of ENOVA and TRANSVAC, VFI is organizing this joined webinar, open to interested people working in the field of veterinary vaccine development.
29. October 2020
10th call for TRANSVAC vaccine development services (TNA)
Deadline 15. December 2020
Access to VFI's Adjuvants and Formulation Services – free of charge.
For more information on VFI services get in touch: contact@vformulation.org
Developing a vaccine is a time-consuming and complex process, requiring a combination of specialized skills and technical capacities not readily available at a single organization. To facilitate access to these skills and capacities, TRANSVAC2 offers high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use. These services are not restricted to any disease area.
- Services will be offered free of charge, with few exceptions!
- Academic and non-academic research groups, SMEs and industries can apply!
- Submission deadline: 15 October 2020
For further information on services available and how to apply please visit www.transvac.org
22. July 2020
New review article “Modulation of immune responses using adjuvants to facilitate therapeutic vaccination”
A collaborative review on Adjuvants in therapeutic vaccination by ENOVA (European Network of Vaccine Adjuvants) members. ENOVA is the European Network of Vaccine Adjuvants, funded by the EC-COST Action CA16231 under the lead of VFI.
24. June 2020
New review article “Technological Approaches for Improving Vaccination Compliance and Coverage”
VFI and ENOVA partners are co-authoring the collaborative review “Technological Approaches for Improving Vaccination Compliance and Coverage”. ENOVA is the European Network of Vaccine Adjuvants, funded by the EC-COST Action CA16231 under the lead of VFI.
27. April 2020
VFI and Seppic announce co-development of a GMP emulsion-based adjuvant for human prophylactic vaccines (including COVID-19 vaccines) on an open-access basis
VFI and Seppic announced that they have finalized the development of an oil-in-water adjuvant at a Seppic plant in France. The adjuvant, manufactured under Good Manufactured Practices, will be openly available from Seppic before the end of this year, for the entire vaccine community.
17. March 2020
VFI supports Sars-Cov-2 vaccine development through TRANSVAC2 (European Commission)
As partner of TRANSVAC2, VFI offers its adjuvant and formulation services to vaccine researchers and developers in the context of Covid-19. Vaccine researchers and developers can ship their Sars-Cov-2 vaccine antigens to VFI for formulation with adjuvants suitable for clinical use. Once optimal formulations are identified, VFI can perform immunogenicity studies in mice including analyses of B- and T-cell responses. First deadline for application is 15 April 2020.
01. March 2020
VFI supports Sars-Cov-2 vaccine development through GH-VAP (Bill & Melinda Gates Foundation)
VFI is working with grantees from the Bill & Melinda Gates Foundation (BMGF) to evaluate Sars-Cov-2 vaccine candidates. Antigens provided by BMGF grantees are appropriately formulated with adjuvants developed by VFI with the ultimate goal to identify suitable Sars-Cov-2 vaccine candidates which can progress towards the clinic. This work is supported by the Global Health Vaccine Accelerator Platforms (GH-VAP) funded by BMGF.
17. February 2020
VFI will actively support the development of vaccines against Covid-19
VFI will support the vaccine community during Covid-19 pandemic. VFI is currently manufacturing several adjuvants to be included in upcoming Covid-19 studies and has secured access to animal facilities for immunogenicity studies of adjuvanted-Sars-Cov-2 vaccine formulations. VFI is also setting up collaborations with numerous vaccine developers worldwide in order to formulate Sars-Cov-2 vaccine candidates with VFI adjuvants to induce relevant immune responses.
13. June 2019
6th call for TRANSVAC vaccine development services (TNA)
Access to VFI's adjuvants and formulation services – free of charge.
TRANSVAC project offers high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use.
Services are offered free of charge! Academic and non-academic research groups, SMEs and industries can apply but only to service infrastructures outside their own country. Submission deadline: 05. August 2019
APPLICATION FORM can be found here.
For services related information please contact the TRANSVAC2 team (transvacinfo@euvaccine.eu) or service providers.
13. June 2019
5th call for TRANSVAC: European training in vaccinology
Deadline for applications 1 July 2019
The fifth call is open until 1st July 2019. It covers 3 modules:
- M10 - Assay Development and Validation - Application of SPR Technologies in Vaccine Development and Manufacturing conducted at Fraunhofer IME, Aachen Germany (10-11 October 2019)
- M11 - Process Development and scale-up of recombinant protein vaccines organized also by Fraunhofer IME, Aachen Germany (7-8 October 2019)
- M12 - Requirements for GMP production, also by Fraunhofer IME, Aachen Germany (14–15 October 2019)
For training related information please contact the TRANSVAC team at transvacinfo@euvaccine.eu
24. May 2019
4th Call for TRANSVAC: European Training in Vaccinology
Deadline for applications 01. June 2019
The fourth call is open from 01. April 2019 – 01. June 2019. It covers 3 modules:
- M6 – CyTOF (Cytometry by time‐of‐flight) conducted at CEA, Fontenay-aux-Roses, France (19-20 September 2019)
- M7 – Flow Cytometry organized also by CEA, Fontenay-aux-Roses, France (18-19 September 2019)
- M9 … Key considerations and best practices for viral vaccine process development, scale-up and implementation at manufacturing scale including single use technologies, organized by VFI together with Merck at Merck/M Lab permises in Molsheim, France (10-11 September 2019)
Participants will be selected by a course selection panel.
The course is offered free of charge. However selected applicants will have to cover their own travel and visa expenses and accommodation (excluding M9, where accommodation will be provided by organizers). Candidates working in a European Union Member State or Associated Member State as well as candidates from other countries who are working in vaccine development projects funded by the European Commission (EC) or European and Developing Countries Clinical trial Partnership (EDCTP) are eligible to apply. Other candidates can also apply, but priority will be given to the groups mentioned above.
For more information about the training modules offered by TRANSVAC, the eligibility criteria and the application process, please visit: www.transvac.org
If you have any specific questions, you can contact the project management team at: transvacinfo@euvaccine.eu
23. May 2019
VFI and Merck provide vaccine process development training courses within TRANSVAC2
TRANSVAC2, part of the EU’s Horizon 2020 program, has set up training modules on vaccine R&D. The full training program and information how to apply can be found on the TRANSVAC website.